Ono Pharmaceutical Co., Ltd.
8-2, Kyutaromachi 1-chome
Chuo-ku
Osaka 541-8564
Japan
81 6 6263 5670
https://www.ono-pharma.com
版塊: Healthcare
行業: Drug Manufacturers - General
全職員工: 3,853
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Gyo Sagara | CEO & Chairman of the Board | 789.15k | 無 | 1958 |
| Mr. Toichi Takino Ph.D. | President, COO & Representative Director | 無 | 無 | 1968 |
| Mr. Masaki Ito | Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax | 無 | 無 | 無 |
| Takehiro Yamada | Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office | 無 | 無 | 無 |
| Masayuki Tanigawa | Corporate Officer & Executive Director of Corporate Development & Strategy | 無 | 無 | 無 |
| Mr. Toshihiro Tsujinaka | Ex. EO, Executive Dir. of Sus. Promotion Corp. Strategy & Planning and Representative Director | 無 | 無 | 1964 |
| Hiromu Habashita Ph.D. | Corporate Officer & Deputy Executive Director, Discovery & Research | 無 | 無 | 無 |
| Kiyoaki Idemitsu | Chief Officer of Clinical Development and Audit & Supervisory Board Member | 無 | 無 | 1964 |
| Shinji Takai M.D., Ph.D. | Corporate Officer & Head of Medical Affairs | 無 | 無 | 無 |
| Satoshi Takahagi | Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division | 無 | 無 | 無 |
描述
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.
公司管治
截至 2024年7月1日 止，Ono Pharmaceutical Co., Ltd. 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：1；董事會：3；股東權利：2；現金賠償：1。
